Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S.A.S. Nagar, Punjab, India.
Healthy Gut Research Group, Centre for Excellence in Functional Foods, Food and Nutritional Biotechnology Division, National Agri-Food Biotechnology Institute, SAS Nagar, Punjab, India; Department of Biotechnology, Panjab University, Chandigarh, India.
Neuropharmacology. 2023 May 15;229:109480. doi: 10.1016/j.neuropharm.2023.109480. Epub 2023 Mar 1.
Gut dysbiosis has been closely linked to the onset and progression of several brain-related disorders such as depression. The administration of microbiota-based formulations such as probiotics helps restore healthy gut flora and plays a role in preventing and treating depression-like behavior. Therefore, we evaluated the efficacy of probiotic supplementation using our recently isolated putative probiotic Bifidobacterium breve Bif11 in ameliorating lipopolysaccharide (LPS)-induced depression-like behavior in male Swiss albino mice. Mice were fed orally with B. breve Bif11 (1 × 10 CFU and 2 × 10 CFU) for 21 days before being challenged with a single intraperitoneal LPS injection (0.83 mg/kg). Behavioral, biochemical, histological and molecular analysis were done with an emphasis on inflammatory pathways linked to depression-like behavior. Daily supplementation with B. breve Bif11 for 21 days prevented the onset of depression-like behavior induced by LPS injection, besides reducing the levels of inflammatory cytokines such as matrix metalloproteinase-2, c-reactive protein, interleukin-6, tumor necrosis factor-alpha and nuclear factor kappa-light-chain-enhancer of activated B cells. It also prevented the decrease of the brain-derived neurotrophic factor levels and neuronal cell viability in the prefrontal cortex of LPS-treated mice. Furthermore, we observed that gut permeability was reduced, there was an improved short-chain fatty acid profile and reduced gut dysbiosis in the LPS mice fed with B. breve Bif11. Similarly, we observed a decrease in behavioural deficits and restoration of gut permeability in chronic mild stress. Together, these results would help in deciphering the role of probiotics in the management of neurological disorders where depression, anxiety and inflammation are prominent clinical features.
肠道菌群失调与多种与大脑相关的疾病的发生和进展密切相关，如抑郁症。给予基于微生物组的制剂，如益生菌，有助于恢复健康的肠道菌群，并在预防和治疗类似抑郁症的行为中发挥作用。因此，我们评估了最近分离的潜在益生菌短双歧杆菌 Bif11 补充剂对改善雄性瑞士白化病小鼠脂多糖（LPS）诱导的类似抑郁症行为的功效。在接受 LPS 单次腹腔注射（0.83mg/kg）之前，用 B. breve Bif11（1×10 CFU 和 2×10 CFU）经口喂养小鼠 21 天。进行行为、生化、组织学和分子分析，重点关注与类似抑郁症行为相关的炎症途径。B. breve Bif11 每日补充 21 天可预防 LPS 注射引起的类似抑郁症行为的发生，此外还可降低炎症细胞因子（如基质金属蛋白酶-2、C 反应蛋白、白细胞介素-6、肿瘤坏死因子-α和核因子 kappa-轻链增强子的活性 B 细胞）的水平。它还可防止 LPS 处理的小鼠前额叶皮层中脑源性神经营养因子水平和神经元细胞活力的下降。此外，我们观察到 LPS 喂养的 B. breve Bif11 可降低肠道通透性，改善短链脂肪酸谱，并减少肠道菌群失调。同样，我们观察到慢性轻度应激的行为缺陷减少和肠道通透性恢复。总之，这些结果有助于阐明益生菌在管理以抑郁、焦虑和炎症为突出临床特征的神经紊乱中的作用。
